EUCTR2005-002126-64-NO进行中（未招募）1 期
An Exploratory Study to Determine Potential Predictive Markers of Response and/orToxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels. Revised Protocol 4 dated 07-Jul-2006 incorporating Protocol Amendments 02, 03, 04 & 05. + Protocol Amendment 1 dated 20-Jul-2005
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Target population
- •a) Able to comply with visits/procedures required by the protocol
- •b) Life expectancy of at least 4 months.
- •c) ECOG performance status score 0-1. (See Appendix 4 of the protocol)
- •d) Histologic or cytologic diagnosis of unresectable Stage III or IV malignant
- •melanoma (excluding ocular melanoma).
- •e) A pre- and post-treatment fresh core or excision tumor biopsy must be provided
- •for biomarker and predictive marker analyses. It is preferred that the biopsies are
- •obtained from the same organ. Note: Site of tumor biopsy should not be the only
- •site of measurable disease.
- •f) Measurable disease as defined in Section 3.3.2.2 of the protocol.
- •g) Required values for initial laboratory tests (see protocol for test details)
- •h) At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,
- •hormonal therapy, radiotherapy or major surgery and the beginning of protocol
- •therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin.
- •i) Toxicity related to prior therapy must either have returned to = grade 1, baseline,
- •or been deemed irreversible.
- •3) Age and Sex
- •a) Men and women, ages 18 and above.
- •Women of childbearing potential (WOCBP) must be using an adequate method of
- •contraception to avoid pregnancy throughout the study in such a manner that the
- •risk of pregnancy is minimized. Suggested precautions should be
- •used to minimize the risk or pregnancy for at least 1 month before dosing, and
- •while women are on study and for up to 12 weeks after last dose of study drug.
- •WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation
- •or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea
- •= 12 consecutive months; or women on hormone replacement therapy (HRT) with
- •documented serum follicle stimulating hormone (FSH) level > 35mIU/mL]. Even women who are using oral, implanted or injectable contraceptive hormones or
- •mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.
- •WOCBP must have a negative pregnancy test (minimum sensitivity 25 IU/L or
- •equivalent units of HCG) within 72 hours prior to the start of study medication.
- •Men must be willing and able to use an acceptable method of birth control, for at
- •least 3 months after completion of the study, if their sexual partners are WOCBP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Sex and Reproductive Status
- •a) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the study;
- •b) WOCBP using a prohibited contraceptive method;
- •c) Women who are pregnant or breastfeeding;
- •d) Women with a positive pregnancy test on enrollment or prior to study drug administration;
- •e) Sexually active fertile men who are unwilling or unable to use an acceptable method of birth control, for the entire study period and for at least 3 months after completion of the study, if their sexual partners are WOCBP.
- •2) Target Disease Exclusion
- •a) Any other malignancy from which the patient has been disease-free for less than
- •5 years, with the exception of adequately treated and cured basal or squamous cell
- •skin cancer, superficial bladder cancer, carcinoma in situ of the cervix;
- •b) Ocular melanoma.
- •3) Medical History and Concurrent Diseases
- •a) Active, untreated central nervous system (CNS) metastasis (including metastasis
- •identified during screening MRI or contrast CT);
- •b) Autoimmune disease: Patients with a history of Inflammatory Bowel Disease are
- •excluded from this study as are patients with a history of autoimmune disease (e.g. Systemic Lupus Erythematosus, vasculitis, infiltrating lung disease) whose possible progression during treatment would be considered by the Investigator to be unacceptable. Patients with a history of well-controlled and/or clinically manageable autoimmune disease (e.g. vitiligo, well-controlled thyroid disease, mild psoriasis) may be considered for inclusion in consultation with the BMS Medical Monitor;
- •c) Any underlying medical condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of
- •adverse events, such as a condition associated with frequent diarrhea;
- •d) Positive screening tests for HIV, HepB, and HepC. If positive results are not indicative of true active or chronic infection, the patient can be admitted after discussion with and agreement by the BMS Medical Monitor;
- •e) Uncontrolled or significant cardiovascular disease including
- •- myocardial infarction within 12 months
- •- uncontrolled angina within 6 months
- •- Class III-IV New York Heart Association (NYHA) congestive heart failure
- •- diagnosed or suspected congenital long QT syndrome
- •- any history of clinically significant ventricular arrhythmias (such as
- •ventricular tachycardia, ventricular fibrillation, or torsade de pointes). Any
- •patient with a history of any arrhythmia should be discussed with the BMS Medical Monitor prior to entry into the study
- •- prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- •- any history of second or third degree heart block (may be eligible if currently have a pacemaker)
- •4) Prohibited Therapies and/or Medications
- •a) Prior exposure to an anti-CTLA4 antibody.
- •b) Use of any immunosuppressing treatments including corticosteroids (patients on
- •stable doses of hormone replacement therapy are exempt), cyclosporine, mycophenolate mofetil (CellCept), chemotherapy, radiation, etc, within 4 weeks
- •prior to Day 1 of treatment.
- •c) Exposure to any investigational drug or placebo within 4 weeks prior to Day 1 of
- •d) Drugs that are generally accepted to have a risk of causing Torsade de Pointes
- •(see Appendix 7). Patients who have discontinued any of these medications must
- •have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is l
研究者
相似试验
进行中（未招募）
不适用
An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels. Revised Protocol 06 dated 11-July-2007 Incorporating Amendment(s) 02, 03, 04, 05, 07 and 08. + Protocol Amendment 1 dated 20-Jul-2005MelanomaEUCTR2005-002126-64-SEBristol-Myers Squibb International Corporation90
已完成
不适用
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)PER-032-06BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
不适用
Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors. - ExplosiveIn addition to the assessment of shunt volumes, the intrahepatic distribution of MAA may allow for prediction of tumor radiation dose and the radiation dose to normal liver tissue. Even though MAA might be suitable for this purpose, recent results question the value of MAA. Using Bremsstrahlen imaging it was demonstrated that the intrahepatic distribution of SIR spheres and MAA differ considerably. The reason for the different deposition pattern of MAA vs. SIR spheres is currently not clear.MedDRA version: 9.1Level: LLTClassification code 10024700Term: Liver metastasesEUCTR2008-005609-21-DEFaculty For Medicine, Otto-von-Guericke University Magdeburg
招募中
不适用
Prospective study on the identification of predictors of efficacy and efficacy/safety of twice-daily inhalers with three components in clinical practice for COPD patients (J-BRAVE)COPD ACOJPRN-UMIN000038169Japanese Red Cross Medical Canter100
招募中
不适用
Prospective study on the identification of predictors of efficacy and efficacy/safety of once-daily inhalers with three components in clinical practice for COPD patients (J-TREND)COPD ACOJPRN-UMIN000038167Japanese Red Cross Medical Canter100